Form 8-K Actavis plc For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Form 8-K Actavis plc For: Feb 18
February 18, 2015 6:47 AM EST
Actavis (NYSE: ACT) provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.
"Today, we provided an overview of the rationalized, standalone pharmaceutical development pipeline that will power Actavis' ascent into the fastest growing and most dynamic growth pharmaceutical company... More
